{"title":"在多能干细胞中抑制n -肉豆蔻酰基转移酶可促进小鼠的初始状态,并在人类中诱导滋养外胚层和原始内胚层标记物。","authors":"Junko Yoshida, Hitomi Watanabe, Kaori Yamauchi, Takumi Nishikubo, Ayako Isotani, Satoshi Ohtsuka, Hitoshi Niwa, Yuki Kawamoto, Hidenori Akutsu, Akihiro Umezawa, Hirofumi Suemori, Yasuhiro Takashima, Hideo Matsuda, Gen Kondoh, Junji Takeda, Kyoji Horie","doi":"10.1016/j.stemcr.2025.102610","DOIUrl":null,"url":null,"abstract":"<p><p>Naive and primed states represent distinct phases of pluripotency during early embryonic development, both of which can be captured and interconverted in vitro. To understand pluripotency regulation, we performed a recessive genetic screen using homozygous mutant mouse embryonic stem cells (mESCs) and identified N-myristoyltransferase (NMT) as a novel regulator. Disruption of Nmt1 in mESCs conferred resistance to differentiation, and NMT suppression in mouse epiblast stem cells (mEpiSCs) promoted the conversion from the primed to the naive state. This effect was independent of proto-oncogene tyrosine-protein kinase Src (SRC), which is a major substrate of NMT and is known to promote mESC differentiation. In contrast, NMT suppression in naive-state human induced pluripotent stem cells (hiPSCs) partially induced naive markers but, more notably, expanded subpopulations expressing trophectoderm and primitive endoderm markers, most of which co-expressed the pluripotency marker POU5F1. These results identify NMT as a novel regulator of pluripotency, with distinct roles in mice and humans.</p>","PeriodicalId":21885,"journal":{"name":"Stem Cell Reports","volume":" ","pages":"102610"},"PeriodicalIF":5.1000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12447342/pdf/","citationCount":"0","resultStr":"{\"title\":\"Inhibition of N-myristoyltransferase in pluripotent stem cells promotes the naive state in mice and elicits trophectoderm and primitive endoderm markers in humans.\",\"authors\":\"Junko Yoshida, Hitomi Watanabe, Kaori Yamauchi, Takumi Nishikubo, Ayako Isotani, Satoshi Ohtsuka, Hitoshi Niwa, Yuki Kawamoto, Hidenori Akutsu, Akihiro Umezawa, Hirofumi Suemori, Yasuhiro Takashima, Hideo Matsuda, Gen Kondoh, Junji Takeda, Kyoji Horie\",\"doi\":\"10.1016/j.stemcr.2025.102610\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Naive and primed states represent distinct phases of pluripotency during early embryonic development, both of which can be captured and interconverted in vitro. To understand pluripotency regulation, we performed a recessive genetic screen using homozygous mutant mouse embryonic stem cells (mESCs) and identified N-myristoyltransferase (NMT) as a novel regulator. Disruption of Nmt1 in mESCs conferred resistance to differentiation, and NMT suppression in mouse epiblast stem cells (mEpiSCs) promoted the conversion from the primed to the naive state. This effect was independent of proto-oncogene tyrosine-protein kinase Src (SRC), which is a major substrate of NMT and is known to promote mESC differentiation. In contrast, NMT suppression in naive-state human induced pluripotent stem cells (hiPSCs) partially induced naive markers but, more notably, expanded subpopulations expressing trophectoderm and primitive endoderm markers, most of which co-expressed the pluripotency marker POU5F1. These results identify NMT as a novel regulator of pluripotency, with distinct roles in mice and humans.</p>\",\"PeriodicalId\":21885,\"journal\":{\"name\":\"Stem Cell Reports\",\"volume\":\" \",\"pages\":\"102610\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12447342/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Stem Cell Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.stemcr.2025.102610\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cell Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.stemcr.2025.102610","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
Inhibition of N-myristoyltransferase in pluripotent stem cells promotes the naive state in mice and elicits trophectoderm and primitive endoderm markers in humans.
Naive and primed states represent distinct phases of pluripotency during early embryonic development, both of which can be captured and interconverted in vitro. To understand pluripotency regulation, we performed a recessive genetic screen using homozygous mutant mouse embryonic stem cells (mESCs) and identified N-myristoyltransferase (NMT) as a novel regulator. Disruption of Nmt1 in mESCs conferred resistance to differentiation, and NMT suppression in mouse epiblast stem cells (mEpiSCs) promoted the conversion from the primed to the naive state. This effect was independent of proto-oncogene tyrosine-protein kinase Src (SRC), which is a major substrate of NMT and is known to promote mESC differentiation. In contrast, NMT suppression in naive-state human induced pluripotent stem cells (hiPSCs) partially induced naive markers but, more notably, expanded subpopulations expressing trophectoderm and primitive endoderm markers, most of which co-expressed the pluripotency marker POU5F1. These results identify NMT as a novel regulator of pluripotency, with distinct roles in mice and humans.
期刊介绍:
Stem Cell Reports publishes high-quality, peer-reviewed research presenting conceptual or practical advances across the breadth of stem cell research and its applications to medicine. Our particular focus on shorter, single-point articles, timely publication, strong editorial decision-making and scientific input by leaders in the field and a "scoop protection" mechanism are reasons to submit your best papers.